Anogenital wart

Author: Jane Morgan MB ChB MRCP FACSHP, Sexual Health Physician, Hamilton, New Zealand, 2003. Updated by Hon A/Prof Amanda Oakley, September 2015.

What is an anogenital wart?

An anogenital wart is a common superficial skin lesion in the anogenital area that is caused by human papillomavirus (HPV). Anogenital warts are also called condyloma acuminata, genital warts, venereal warts and squamous cell papilloma.

What is the human papillomavirus?

The human papillomavirus (HPV) is actually a group of double-stranded DNA viruses.

Who gets anogenital warts?

As anogenital warts are sexually acquired during close skin contact, they are most commonly observed in young adults between the ages of 15 and 30 years. They are highly contagious, and occur in equal numbers in unvaccinated males and females. However, they are rare in people that have been vaccinated against HPV in childhood before beginning sexual activity.

What does an anogenital wart look like?

An anogenital wart is a flesh coloured papule a few millimetres in diameter. Warts may join together to form plaques up to several centimetres across.

They may occur in the following sites:

Warts due to the same types of HPV can also arise on the lips or within the oral mucosa.

See images of genital warts ...

Normal anatomical structures may be confused with warts. These include:

How is HPV transmitted?

Visible genital warts and subclinical HPV infection nearly always arise from direct skin to skin contact.

Often, warts will appear three to six months after infection but they may appear months or even years later.

How can transmission of warts be reduced?

Transmission of warts to a new sexual partner can be reduced but not completely prevented by using condoms. Condoms do not prevent all genital skin-to-skin contact, but they also protect against other STDs.

Successful treatment of the warts decreases the chance of passing on the infection.

How are genital warts diagnosed?

Genital warts are usually diagnosed clinically.

Biopsy is sometimes necessary to confirm the diagnosis or viral wart or to diagnose an associated cancer.

In some circumstances, researchers and clinicians may wish to confirm the presence or absence of HPV. One commercially available qualitative test for HPV is the COBAS 4800 Human Papillomavirus (HrHPV) Test, which evaluates 14 high-risk (HR oncogenic) HPV types. A negative test excludes high-risk infection.

What is the treatment for genital warts?

The primary goal of treatment is to eliminate warts that cause physical or psychological symptoms such as:

Options include:

The underlying viral infection may persist after the visible warts have cleared. Warts sometimes re-emerge years later because the immune system has weakened.

Self-applied treatments

To be successful the patient must identify and reach the warts, and follow the application instructions carefully. Available treatments include:

Treatment at the clinic

in-clinic treatments include:

Experimental therapies for genital warts include:

Genital warts and cancer

The HPV types that cause external visible warts (HPV Types 6 and 11) rarely cause cancer. Other HPV types (most often Types 16, 18, 31, 33 and 35) are less common in visible warts but are strongly associated with anogenital cancer, including:

HPV also causes some cases of oral and nasopharyngeal cancer.

Only a small percentage of infected people develop genital cancer. This is because HPV infection is only one factor in the process; cigarette smoking and how well the immune system is working are also important.

Cervical smears, as recommended in the National Cervical Screening guidelines, detect squamous intraepithelial lesions of the cervix, which can be treated. If these abnormalities were ignored over a long period, they could progress to cervical cancer.

Human papillomavirus vaccine

Several vaccines are available to prevent HPV infection.

HPV vaccination is most effective when offered at a young age, before the onset of sexual activity. However, girls that are already sexually active may not have been infected with the types of HPV covered by the vaccine and may still benefit from vaccination. Women that receive HPV vaccine should continue to participate in cervical screening programmes, as about 30% of cervical cancers will not be prevented by the vaccine.

HPV vaccines are also effective in boys. Vaccination of boys is recommended to reduce transmission of HPV to unvaccinated females. It also reduces the incidence of cancers related to HPV infection.

There has been interest in developing therapeutic HPV vaccines for the treatment of genital warts and cervical cancer in those already infected, and for other strains of HPV that are associated with other forms of viral warts.

Related information

Email Newsletter

Would you like to receive our dermatology updates by email?


Submit your images

We're seeking high-quality photos of skin diseases.  


Machine diagnosis

Watch DermNet's proposal to create a 'Skin Disease Image Recognition Tool' - winner of the 2017 'Clinicians' Challenge Active Award' by the NZ Ministry of Health and HiNZ.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter